Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 2Breast Neoplasms 2Recurrence 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Melanoma 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × poly(I).poly(c12,U) × Clear all
NCT01545141 2023-10-27

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
15 enrolled 9 charts
Gastrointestinal

Neoplasm Metastasis, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡